Top Markets
Coin of the day
Thalia Therapeutics Plc Thalia Therapeutics Plc

Thalia Therapeutics Plc

THAT
株式のランク #40823
Thalia Therapeutics Plc, a specialized pharmaceutical company established in... Thalia Therapeutics Plc, a specialized pharmaceutical company established in 1979 and headquartered in Chellaston, UK, focuses on developing advanced nanoparticle silica delivery systems. These innovative systems are designed to enhance the cellular uptake and effectiveness of various cancer treatments and vaccines. The company's product portfolio includes Nuvec, a unique silica nanoparticle delivery platform distinguished by its irregular surface structure that effectively encapsulates and safeguards genetic material such as siRNA, RNA, and DNA. Additionally, it offers Liptide, a specialized platform engineered for the targeted delivery of a proprietary siRNA sequence to silence fibrotic genes. Thalia Therapeutics is also advancing N4 101, an orally administered inflammation inhibitor currently undergoing pre-clinical evaluation for the treatment of inflammatory bowel disease, alongside ECP105, which is being developed to prevent ocular scarring. The firm, previously known as N4 Pharma Plc, officially rebranded to Thalia Therapeutics Plc in March 2026.
株価
$0.00918474
時価総額
$76.44K
変化(1日)
0.00%
変化(1年)
38.04%
GB
取引 Thalia Therapeutics Plc (THAT)

カテゴリー

Thalia Therapeutics Plc(THAT)の利益
2026 時点の利益 TTM: 0
Thalia Therapeutics Plc の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Thalia Therapeutics Plc の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益